InsiderTrades.com logo
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
From Crypto Swap Profits   |   Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Thomas W. Dubensky net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Thomas Dubensky Biography and Net Worth

President of Tempest Therapeutics
Dr. Dubensky was the founding CEO of Tempest, joining the Company in 2017. He brings significant expertise in the discovery, development and translation of novel small molecule-, biologic- and vector-based cancer therapies, having advanced several first-in-human drug candidates. Dr. Dubensky previously held roles leading discovery biology, development and clinical translation in cancer immunotherapy and infectious disease indications at multiple biotech companies, including Viagene, Chiron, Onyx, Cerus and Immune Design. He has an extensive publication and patent record. Dr. Dubensky received his BA in Bacteriology and Immunology from the University of California, Berkeley, his PhD at the University of Colorado Health Sciences Center, conducted his post-doctoral studies at Harvard Medical School in the Department of Pathology and received executive training at the University of California, San Diego, Executive Program for Scientists and Engineers.

What is Thomas W. Dubensky's net worth?

The estimated net worth of Thomas W. Dubensky is at least $73,175.27 as of August 11th, 2017. Dr. Dubensky owns 80,812 shares of Tempest Therapeutics stock worth more than $73,175 as of November 23rd. This net worth evaluation does not reflect any other investments that Dr. Dubensky may own. Learn More about Thomas W. Dubensky's net worth.

How do I contact Thomas W. Dubensky?

The corporate mailing address for Dr. Dubensky and other Tempest Therapeutics executives is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. Tempest Therapeutics can also be reached via phone at 415-798-8589 and via email at [email protected]. Learn More on Thomas W. Dubensky's contact information.

Has Thomas W. Dubensky been buying or selling shares of Tempest Therapeutics?

Thomas W. Dubensky has not been actively trading shares of Tempest Therapeutics during the last ninety days. Most recently, on Friday, January 7th, Thomas W. Dubensky bought 2,000 shares of Tempest Therapeutics stock. The stock was acquired at an average cost of $4.78 per share, with a total value of $9,560.00. Learn More on Thomas W. Dubensky's trading history.

Are insiders buying or selling shares of Tempest Therapeutics?

In the last year, Tempest Therapeutics insiders bought shares 3 times. They purchased a total of 47,172 shares worth more than $100,001.36. In the last year, insiders at the sold shares 2 times. They sold a total of 787,999 shares worth more than $966,798.90. The most recent insider tranaction occured on August, 12th when Major Shareholder Versant Venture Capital Vi, L. sold 387,999 shares worth more than $426,798.90. Insiders at Tempest Therapeutics own 4.7% of the company. Learn More about insider trades at Tempest Therapeutics.

Information on this page was last updated on 8/12/2024.

Thomas W. Dubensky Insider Trading History at Tempest Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/7/2022Buy2,000$4.78$9,560.00View SEC Filing Icon  
See Full Table

Thomas W. Dubensky Buying and Selling Activity at Tempest Therapeutics

This chart shows Thomas W Dubensky's buying and selling at Tempest Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tempest Therapeutics Company Overview

Tempest Therapeutics logo
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Read More

Today's Range

Now: $0.91
Low: $0.87
High: $0.93

50 Day Range

MA: $1.15
Low: $0.85
High: $1.51

2 Week Range

Now: $0.91
Low: $0.80
High: $6.00

Volume

741,175 shs

Average Volume

2,099,844 shs

Market Capitalization

$39.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Financial Prophecy
From Porter & Company   |   Ad
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
Including the name of the #1 company to buy.